Re-analysis of expression profiles for revealing new potential candidate genes of heart failure

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 7, 2013, Pages 903-911

  Chen, H B ^a   Wang, L ^b   Jiang, J F ^a  

^a TONGJI UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Heart failure; Microarray data; Pathway; Regulation network

Indexed keywords

CARISOPRODOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; DNA MICROARRAY; GENE EXPRESSION; HEART FAILURE; HUMAN; MICROARRAY ANALYSIS; ONCOGENE MYC;

ANTIGENS, DIFFERENTIATION; CHEMOKINE CCL2; GENE REGULATORY NETWORKS; GENES, MYC; HEART FAILURE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; TRANSCRIPTOME;

EID: 84878621800     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. OWEN KL, PRETORIUS L, MCMULLEN JR. The protective effects of exercise and phosphoinositide 3-kinase (p110alpha) in the failing heart. Clin Sci (Lond) 2009; 116: 365-375.
2. MANN DL, BRISTOW MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005; 111: 2837-2849.
3. HILFIKER-KLEINER D, LANDMESSER U, DREXLER H. Molecular mechanisms in heart failure: Focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 2006; 48: A56-A66.
4. YUNG CK, HALPERIN VL, TOMASELLI GF, WINSLOW RL. Gene expression profiles in end-stage human idiopathic dilated cardiomyopathy: Altered expression of apoptotic and cytoskeletal genes. Genomics 2004; 83: 281-297.
5. MULLER DV, ANDERSEN PS, HEDLEY P, ERSBØLL MK, BUNDGAARD H, MOOLMAN-SMOOK J, CHRISTIANSEN M, KØBER L. The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy. Eur J Human Genetics 2009; 17: 1241-1249.
6. NEGLIA D, L'ABBATE A. Coronary microvascular dysfunction and idiopathic dilated cardiomyopathy. Pharmacol Rep 2005; 57: 151-155.
7. VANDERHEYDEN M, PAULUS W, VOSS M, KNUEFERMANN P, SIVASUBRAMANIAN N, MANN D, BAUMGARTEN G. Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. Heart 2005; 91: 926-931.
8. FUJIOKA S, KITAURA Y, UKIMURA A, DEGUCHI H, KAWAMURA K, ISOMURA T, SUMA H, SHIMIZU A. Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000; 36: 1920-1926.
9. UENO A, MURASAKI K, HAGIWARA N, KASANUKI H. Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyophthy. Heart Vessels 2007; 22: 316-321.
10. SPIES M, DASU MR, SVRAKIC N, NESIC O, BARROW RE, PEREZ-POLO JR, HERNDON DN. Gene expression analysis in burn wounds of rats. Am J Physiol Regul Integr Comp Physiol 2002; 283: R918-930.
11. XU J, NIE HG, ZHANG XD, TIAN Y, YU B. Down-regulated energy metabolism genes associated with mitochondria oxidative phosphorylation and fatty acid metabolism in viral cardiomyopathy mouse heart. Mol Biol Rep 2011; 38: 4007-4013.
12. MIN K-D, ASAKURA M, LIAO Y, NAKAMARU K, OKAZAKI H, TAKAHASHI T, FUJIMOTO K, ITO S, TAKAHASHI A, ASANUMA H. Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophy Res Commun 2010; 393: 55-60.
13. VERDUCCI JS, MELFI VF, LIN S, WANG Z, ROY S, SEN CK. Microarray analysis of gene expression: considerations in data mining and statistical treatment. Physiol Genomics 2006; 25: 355-363.
14. LU B, YU H, ZWARTBOL M, RUIFROK WP, VAN GILST WH, DE BOER RA, SILLJÉ HH. Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. Physiol Genomics 2012; 44: 443-454.
15. WACHI S, YONEDA K, WU R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005; 21: 4205-4208.
16. KANEHISA M. The kegg database. Novartis Found Symp 2002; 247: 91-101; discussion 101-103, 119-128, 244-152.
17. BRIVANLOU AH, DARNELL JE, JR. Signal transduction and the control of gene expression. Science 2002; 295: 813-818.
18. WINGENDER E. The transfac project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinform 2008; 9: 326-332.
19. JIANG C, XUAN Z, ZHAO F, ZHANG MQ. Tred: A transcriptional regulatory element database, new entries and other development. Nucleic Acids Res 2007; 35: D137-140.
20. SMYTH GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3.
21. MAERE S, HEYMANS K, KUIPER M. Bingo: A cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005; 21: 3448-3449.
22. SHANNON P, MARKIEL A, OZIER O, BALIGA NS, WANG JT, RAMAGE D, AMIN N, SCHWIKOWSKI B, IDEKER T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
23. DRAGHICI S, KHATRI P, TARCA AL, AMIN K, DONE A, VOICHITA C, GEORGESCU C, ROMERO R. A systems biology approach for pathway level analysis. Genome Res 2007; 17: 1537-1545.
24. TAVAZOIE S, HUGHES JD, CAMPBELL MJ, CHO RJ, CHURCH GM. Systematic determination of genetic network architecture. Nat Genet 1999; 22: 281-285.
25. DRAGHICI S, KHATRI P, MARTINS RP, OSTERMEIER GC, KRAWETZ SA. Global functional profiling of gene expression. Genomics 2003; 81: 98-104.
26. LEE HG, CHEN Q, WOLFRAM JA, RICHARDSON SL, LINER A, SIEDLAK SL, ZHU X, ZIATS NP, FUJIOKA H, FELSHER DW, CASTELLANI RJ, VALENCIK ML, MCDONALD JA, HOIT BD, LESNEFSKY EJ, SMITH MA. Cell cycle re-en- try and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. PLoS One 2009; 4: e7172.
27. KROUMPOUZOU E, GOMATOS IP, KATAKI A, KARAYANNIS M, DANGAS GD, TOUTOUZAS P. Common pathways for primary hypertrophic and dilated cardiomyopathy. Hybrid Hybridomics 2003; 22: 41-45.
28. DZIMIRI N, AL-BAHNASI K, AL-HALEES Z. Myocardial hypertrophy is not a prerequisite for changes in early gene expression in left ventricular volume overload. Fundam Clin Pharmacol 2004; 18: 39-44.
29. KOBAYASHI M, NAKAMURA K, KUSANO KF, NAKAMURA Y, OHTA-OGO K, NAGASE S, SAKURAGI S, OHE T. Expression of monocyte chemoattractant protein-1 in idiopathic dilated cardiomyopathy. Int J Cardiol 2008; 126: 427-429.
30. OGIMOTO A, OKAYAMA H, NAGAI T, OHTSUKA T, SUZUKI J, INOUE K, NISHIMURA K, SHIGEMATSU Y, TABARA Y, KOHARA K, MIKI T, HIGAKI J. Association of monocyte chemoattractant protein 1 gene polymorphism with susceptibility to nonfamilial idiopathic dilated cardiomyopathy. J Cardiol 2009; 54: 66-70.
31. STEENBERGEN C, AFSHARI CA, PETRANKA JG, COLLINS J, MARTIN K, BENNETT L, HAUGEN A, BUSHEL P, MURPHY E. Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am J Physiol Heart Circ Physiol 2003; 284: H268-276.
32. KOTOOKA N, INOUE T, AOKI S, ANAN M, KOMODA H, NODE K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008; 130: 19-22.
33. FRANTZ S, FRACCAROLLO D, WAGNER H, BEHR TM, JUNG P, ANGERMANN CE, ERTL G, BAUERSACHS J. Sustained activation of nuclear factor kappa b and activator protein 1 in chronic heart failure. Cardiovasc Res 2003; 57: 749-756.
34. HERRON BJ, RAO C, LIU S, LAPRADE L, RICHARDSON JA, OLIVIERI E, SEMSARIAN C, MILLAR SE, STUBBS L, BEIER DR. A mutation in nfkb interacting protein 1 results in cardiomyopathy and abnormal skin development in wa3 mice. Hum Mol Genet 2005; 14: 667-677.
35. ROURA S, PLANAS F, PRAT-VIDAL C, LETA R, SOLER-BOTIJA C, CARRERAS F, LLACH A, HOVE-MADSEN L, PONS LLADO G, FARRE J, CINCA J, BAYES-GENIS A. Idiopathic dilated cardiomyopathy exhibits defective vascularization and vessel formation. Eur J Heart Fail 2007; 9: 995-1002.
36. LEVIN MJ, HOEBEKE J. Cross-talk between anti-beta1- adrenoceptor antibodies in dilated cardiomyopathy and chagas' heart disease. Autoimmunity 2008;41:429-433.
37. TSIPIS A, ATHANASSIADOU AM, ATHANASSIADOU P, KAVANTZAS N, AGROGIANNIS G, PATSOURIS E. Apoptosisrelated factors p53, bcl-2 and the defects of force transmission in dilated cardiomyopathy. Pathol Res Pract 2010; 206: 625-630.
38. ZORC M, VRASPIR-PORENTA O, ZORC-PLESKOVIC R, RADOVANOVIC N, PETROVIC D. Apoptosis of myocytes and proliferation markers as prognostic factors in end-stage dilated cardiomyopathy. Cardiovasc Pathol 2003; 12: 36-39.
39. YUCEL D, AYDOGDU S, CEHRELI S, SAYDAM G, CANATAN H, SENES M, CIGDEM TOPKAYA B, NEBIOGLU S. Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem 1998; 44: 148-154.